argenx SE (ARGX) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

22/25

Growth 5 Margin 5 Expansion 4 Platform 3 Financial 5

latest quarter score

Earnings Reports

22
ARGX Q2 2026: VivGuard Drives 60% Revenue Surge as Seronegative GMG Approval Expands Market
July 24, 2026
23
ARGX Q1 2026: $400M Cash Build and 90% Gross Margin Underscore Pipeline-Driven Immunology Expansion
May 07, 2026
21
ARGX Q4 2025: VivGuard Drives 90% Growth as Ocular MG Approval Targets 7,000-Patient Expansion
February 26, 2026
22
ARGX Q3 2025: Pre-Filled Syringe Drives 20% U.S. Growth, Expands Neurology Leadership
October 30, 2025
16
ARGX Q2 2025: Pre-Filled Syringe Drives 19% Sequential Growth, Expanding Patient Reach
July 31, 2025
22
ARGX Q1 2025: Pre-Filled Syringe Drives 50% New Patient Uptake, Expanding Market Reach
July 06, 2025
ARGX Q3 2024: CIDP Launch Adds 300 Patients, Validating Switch Market Strategy
October 31, 2024
ARGX Q2 2024: VivGuard Drives 20% QoQ Sales Jump, CIDP Launch Sets Stage for Multi-Indication Growth
July 25, 2024
ARGX Q1 2024: Vivgard Patient Base Surpasses 10,000 as Subcutaneous Uptake Accelerates 34%
May 09, 2024
ARGX Q4 2023: VivGuard Drives $1.2B U.S. Revenue as Pipeline Readies for Five New Indications
February 29, 2024
ARGX Q3 2023: Hytrulo Drives 22% Sequential Growth as Indication Expansion Accelerates
October 31, 2023
ARGX Q2 2023: VivGuard Sales Climb to $489M as SubQ Launch Unlocks Community Expansion
July 27, 2023
ARGX Q1 2023: SubQ Launch and 5th Approval Expand VivGuard’s Global Reach
May 04, 2023
ARGX Q4 2022: VivGuard Reaches 3,000 Patients, Fueling Multinational Expansion and Pipeline Leverage
March 02, 2023

Browse all companies